John Timmerman, MD | Authors

Hematologic Cancers Break Down a ‘Checkpoint’: Targeting the PD-1/PD-L1 Axis

June 15, 2015

While the results of the multitude of ongoing PD-1 blockade trials are eagerly awaited, it is clear that research involving the immunotherapy of blood cancers is moving swiftly through this first “checkpoint” at breakneck speed. It is sure to be a fascinating ride.